Atherosclerosis-targeted liposome nanocarrier delivery system and preparation method therefor
US-2024424132-A1 · Dec 26, 2024 · US
Method for administration
US2021069149A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2021069149-A1 |
| Application number | US-202016951153-A |
| Country | US |
| Kind code | A1 |
| Filing date | Nov 18, 2020 |
| Priority date | Mar 19, 2012 |
| Publication date | Mar 11, 2021 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
First claim
Opening claim text (preview).
What is claimed: 1 . A method of treating a patient suffering form cancer, comprising administering to said patient a pharmaceutical composition containing as an active ingredient Compound A in an amount from about 800 mg/day to about 3000 mg/day, daily, for up to about 7 days, followed by a rest period of up to about 21 days, said administration starting on the first day of a 28 day treatment cycle. 2 . A method of treating a patient suffering form cancer, comprising administering to said patient a pharmaceutical composition containing as an active ingredient Compound A in an amount from about 800 mg/day to about 3000 mg/day, daily, for up to about 5 days, followed by a rest period of up to about 23 days, said administration starting on the first day of a 28 day treatment cycle. 3 . The method of claim 2 wherein Compound A is administered in an amount from about 1000 mg/day to about 2500 mg/day. 4 . The method of claim 3 wherein Compound A is administered in an amount of from about 1250 mg/day to about 1800 mg/day. 5 . The method of claim 1 wherein the treatment cycle being repeated every 28 days for up to about 12 cycles. 6 . The method of claim 1 wherein Compound A is administered twice daily in equal doses. 7 . The method of claim 1 wherein the cancer is colorectal cancer. 8 . The method of claim 1 wherein the cancer is prostate cancer. 9 . The method of claim 1 wherein the cancer is lung cancer. 10 . The method of claim 1 wherein the cancer is kidney cancer. 11 . The method of claim 1 wherein the cancer is breast cancer.
Assignees
Inventors
Classifications
- A61K31/40Primary
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title
with organic macromolecular compounds · CPC title
Antineoplastic agents · CPC title
- A61K31/401Primary
Proline; Derivatives thereof, e.g. captopril · CPC title
Preparations for use in therapy · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2021069149A1 cover?
- There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
- Who is the assignee on this patent?
- Hoffmann La Roche
- What technology area does this patent fall under?
- Primary CPC classification A61K31/40. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Mar 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).